Famicord Ag · XETR:V3V
Famicord — Vita 34 — Investor Presentation (April 2022)
19 slides from Famicord's investor presentation, April 2022
Slide 1: Vita 34 – The Cell Bank: How to Become a Global Leader
VITA 34 – THE CELL BANK HOW TO BECOME A GLOBAL LEADER INVESTOR PRESENTATION, APRIL 2022 INVESTOR PRESENTATION, APRIL 2022 1 1
Slide 2: Focus Points of Equity Story
FOCUS POINTS OF EQUITY STORY Founded in 1997, the Vita 34 Group today is the Vita 34 - pure growth from day 1 leading cell bank in Europe with around 850.000 Development of total cell storages total cell storages and clients from more than 20 countries Pioneering the cord blood banking industry
Slide 3: General Business Model – Storage Process
GENERAL BUSINESS MODEL – STORAGE PROCESS Present process from customer acquisition to storage, adaptable also for new product segments 1. 2. 3. 4. 5. 6. Information Order via Collection in Shipping to Processing in Storage in via doctors, Internet, partner Vita 34 the laboratory, controlled midwives
Slide 4: General Business Model – Critical Success Factors
GENERAL BUSINESS MODEL – CRITICAL SUCCESS FACTORS High Market Sophisticated Coverage Technology High market coverage of clinics High cell yield (e.g. Germany ~82% of maternity clinics) Autologous and allogenic use Market partnerships provide further upside Technology transfer is key to new
Slide 5: Business Combination with PBKM – Forging the Future Global Leader
BUSINESS COMBINATION WITH PBKM – FORGING THE FUTURE GLOBAL LEADER 2017 – 2020 31 May 2021 20 September 2021 18 November 2021 Occasional talks between Vita 34 and PBKM sign business Start of public exchange Transaction settlement Vita 34 and PBKM combination agreement offer for PBKM shares 7 July 202
Slide 6: Business Combination with PBKM – Merger Benefits
BUSINESS COMBINATION WITH PBKM – MERGER BENEFITS REVENUES Strong unified German presence SYNERGIES Cross selling via access to experimental therapies in EU (Poland) to Vita clients and leveraging PBKM’s experience in therapies and CDMO on German market Shared experiences with contract renewals
Slide 7: European Market Coverage of the Combined Entity
EUROPEAN MARKET COVERAGE OF THE COMBINED ENTITY Business combination forges clearly dominant ~80% European market leader & market coverage in Europe Perfect match: only ~15% overlap in operational business Operationally ideal setup: main activities in the heart of Europe Strong cash flow fro
Slide 8: New Storages, Recurring Revenues & High Impact of Contract Renewals
NEW STORAGES, RECURRING REVENUES & HIGH IMPACT OF CONTRACT RENEWALS Simplified illustration of revenue streams About 45% of customers choose up-front payment ( one-time revenue) vs.55% yearly payment contracts ( recurring revenue) Revenues Start of contract renewal Up-front payment contract us
Slide 9: Organically Grown & Acquired Customers Fuel Future Recurring Revenues
ORGANICALLY GROWN & ACQUIRED CUSTOMERS FUEL FUTURE RECURRING REVENUES NUMBER OF CUSTOMERS IN SUBSCRIPTION PRICE MODELS Existing prepayment client base and organic client acquisition Potential clients 2017 2018 2019 2020 Organic Expiring Potential M&A Former Potential growth prepayment subscription C
Slide 10: Development of Revenues and EBITDA
DEVELOPMENT OF REVENUES AND EBITDA Revenues (in mEUR) EBITDA (in mEUR) 70 ~65 12 ~10,8 60 10 50 8 40 5,9 6 5,4 4,7 30 19,2 20,4 20,2 20,2 4 3,3 20 10 2 0 0 2017 2018 2019 2020 2021e* 2017* 2018 2019 2020* 2021e** * Aggregate mid-ranges of former official revenues guidances of Vita 34 and PBKM combin
Slide 11: From Cell Storage to Drug Innovation: ATMP-HE and Unique Therapy Development
FROM CELL STORAGE TO DRUG INNOVATION: ATMP-HE AND UNIQUE THERAPY DEVELOPMENT Complementary R&D projects form basis for vast new business opportunities 10 R&D projects 1st clinical trial of CARLA approved in progress (CAR-T Therapy) ~2,000 patients in 1st clinical trial of ALSTEM successful, experime
Slide 12: New Group with Even Broader Cell-Oriented Portfolio
NEW GROUP WITH EVEN BROADER CELL-ORIENTED PORTFOLIO From perinatal focus to comprehensive service provider in personalized medicine Stem cells Adipose tissue* Immune cells* CAR-T / SVF Preservation of stem Preservation of Preservation of Development of CAR-T cell cells from perinatal stem cells from
Slide 13: Forecast & Dividend Marked by Clear Growth Course
FORECAST & DIVIDEND MARKED BY CLEAR GROWTH COURSE Revenue 2021e aEBITDA 2021e EUR 20.3 – 22.3 m EUR 5.5 – 6.1 m 2021 forecast cancelled in November 2021 against background of business combination Unchanged positive development of operating business; however, in the absence of consolidated busine
Slide 14: Potential Not Yet Reflected in Share Price Development
POTENTIAL NOT YET REFLECTED IN SHARE PRICE DEVELOPMENT 18,00 SDAX (ind.) Vita 34 AG (XETRA) Management & 17,00 Supervisory Board 4,3% 16,00 30,7% AOC Health GmbH* 15,00 14,00 Nationale-Nederlanden 13,00 Powszechne 55,0% Towarzystwo Emerytalne 10,0% 12,00 S.A. 11,00 Freefloat 10,00 Jan. 21 Apr. 21 Ju
Slide 15: Technological Appendix
TECHNOLOGICAL APPENDIX INVESTOR PRESENTATION, APRIL 2022 15 15
Slide 16: New Product “Immune Cells” & Economic Rational
NEW PRODUCT “IMMUNE CELLS” & ECONOMIC RATIONAL New structure following STEM CELLS approval process IMMUNE CELLS Rationale behind the new product Cryo-preservation of immune cells from peripheral blood offers the chance of conserving immune cells for everybody GMP process (blood sampling, transpo
Slide 17: Factors Affecting CAR-T Product Quality
FACTORS AFFECTING CAR-T PRODUCT QUALITY Age X T cell number Up to 10% X T cell dysfuncftion of patients might Condition not be eligible X T cell exhaustion for CAR-T cell Diseases manufacturing! X T cell phenotype Early collection, processing & storage improve CAR-T quality optimization of start
Slide 18: Immune Cell Therapies – A Big Step Towards Personalized Medicine
IMMUNE CELL THERAPIES – A BIG STEP TOWARDS “PERSONALIZED MEDICINE” Blood T cell isolation T cell T cell expansion Preconditioning collection & activation modification & product & T cell formulation infusion Increasing impact in anti-cancer therapies CAR-T Immunotherapies approved by FDA and EMA Ky
Slide 19: Contact: Vita 34 AG
Contact: Vita 34 AG Ingo Middelmenne Investor Relations Perlickstraße 5 04103 Leipzig Tel. +49 341 48792 7574 Fax +49 341 48792 39 E-Mail: ingo.middelmenne@vita34.de www.vita34.de INVESTOR PRESENTATION, APRIL 2022 19 19